Novel aspects of native and recombinant allergens and their therapeutic implications:
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Philadelphia, Pa. [u.a.]
Saunders
2007
|
| Series: | Immunology and allergy clinics of North America
27,1 |
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | XVIII, 144 S. Ill., graph. Darst. |
| ISBN: | 141604325X 9781416043256 |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV022361898 | ||
| 003 | DE-604 | ||
| 005 | 20070411 | ||
| 007 | t | ||
| 008 | 070322s2007 ad|| |||| 00||| eng d | ||
| 020 | |a 141604325X |9 1-4160-4325-X | ||
| 020 | |a 9781416043256 |9 978-1-4160-4325-6 | ||
| 035 | |a (OCoLC)93806013 | ||
| 035 | |a (DE-599)BVBBV022361898 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-29 | ||
| 050 | 0 | |a RC583 | |
| 082 | 0 | |a 616.0798 |2 22 | |
| 084 | |a XD 2800 |0 (DE-625)152549:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Novel aspects of native and recombinant allergens and their therapeutic implications |c guest ed.: Sanjiv Sur |
| 264 | 1 | |a Philadelphia, Pa. [u.a.] |b Saunders |c 2007 | |
| 300 | |a XVIII, 144 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Immunology and allergy clinics of North America |v 27,1 | |
| 650 | 4 | |a Allergens | |
| 650 | 4 | |a Allergens |x immunology | |
| 650 | 4 | |a Allergens |x therapeutic use | |
| 650 | 4 | |a Antigens | |
| 650 | 4 | |a Hypersensitivity |x therapy | |
| 650 | 4 | |a Recombinant Proteins |x immunology | |
| 650 | 4 | |a Recombinant Proteins |x therapeutic use | |
| 650 | 0 | 7 | |a Allergen |0 (DE-588)4001255-4 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Allergen |0 (DE-588)4001255-4 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Sur, Sanjiv |e Sonstige |4 oth | |
| 830 | 0 | |a Immunology and allergy clinics of North America |v 27,1 |w (DE-604)BV000645505 |9 27,1 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015571225&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015571225 | ||
Record in the Search Index
| _version_ | 1804136410732560384 |
|---|---|
| adam_text | NOVEL ASPECTS OF NATIVE AND RECOMBINANT ALLERGENS
AND THEIR THERAPEUTIC IMPLICATIONS
CONTENTS
Foreword xiii
Rafeul Alam
Preface xv
Sanjiv Sur
Bioinformatics Approaches to Classifying Allergens
and Predicting Cross Reactivity 1
Catherine H. Schein, Ovidiu Ivanciuc, and Werner Braun
Allergenic proteins from very different environmental sources have
similar sequences and structures. This fact may account for multi¬
ple allergen syndromes, whereby a myriad of diverse plants and
foods may induce a similar IgE based reaction in certain patients.
Identifying the common triggering protein in these sources, in sil
ico, can aid designing individualized therapy for allergen sufferers.
This article provides an overview of databases on allergenic pro¬
teins, and ways to identify common proteins that may be the cause
of multiple allergy syndromes. The major emphasis is on the rela¬
tional Structural Database of Allergenic Proteins (SDAP |http:/7
fermi.utmb.edu/SDAP/]), which includes cross referenced data
on the sequence, structure, and IgE epitopes of over 800 allergenic
proteins, coupled with specially developed bioinformatics tools to
group all allergens and identify discrete areas that may account for
cross reactivity. SDAP is freely available on the Web to clinicians
and patients.
Calcium Binding Proteins and their Role in Allergic Diseases 29
Nicole Wopfner, Oliver Dissertori, Fatima Ferreira,
and Peter Lackner
Calcium binding proteins (CBPs) are ubiquitous pollen aller¬
gens and important food allergens in fish and amphibians.
VOLUME 27 • NUMBER 1 • FEBRUARY 2007 vii
Calcium binding allergens containing two EF hands (polcalcins)
have been detected and characterized in pollen from trees, grasses,
and weeds. Timothy grass Phi p 7 is the most cross reactive
allergen among polcalcins. Although there is cross reactivity de¬
scribed within the subfamilies of calcium binding allergens, there
are no strong indications for IgE cross reactivity between CBPs
from plants, fish, and humans. Therefore, Phi p 7 could be used
as marker to identify multiple pollen sensitized patients, whereas
cod Gad c 1 or carp Cyp c 1 could be selected for the diagnosis
of fish allergy. Horn s 4, a calcium binding autoantigen, might be
an interesting candidate to monitor chronic skin inflammation in
atopic and nonatopic individuals. Diagnostic tests containing these
molecules could allow the identification of most patients sensitized
to calcium binding allergens/antigens. In general, IgE recognition
of calcium binding allergens is influenced by binding or release
of calcium ions. This knowledge could be used to engineer hypoal
lergenic CBPs for specific immunotherapy.
Pollen NAD(P)H Oxidases and their Contribution
to Allergic Inflammation 45
Nilesh G. Dharajiya, Attila Bacsi, Istvan Boldogh,
and Sanjiv Sur
This article provides an overview of NADPH oxidase and its role in
allergic inflammation. A background and historical perspectives of
NADPH oxidase are first provided, followed by a detailed over¬
view of mammalian NADPH oxidase subunits and their functional
organization. Plant NADPH oxidase, the authors discovery of
NADPH oxidase in pollens, and their contribution to allergic in¬
flammation are then discussed, concluding with a discussion of fu¬
ture directions and outstanding questions that require attention.
Impact of Native, Recombinant, and Cross Reactive Allergens
on Humoral and T Cell—Mediated Immune Responses 65
Reto Crameri and Claudio Rhyner
Many native allergens have been purified to homogeneity from
natural sources, and whole arrays of recombinant and cross reac¬
tive allergens have been produced in large amounts as biologically
active molecules. These allergens offer potent research tools to in¬
vestigate humoral and Tcell—mediated immune responses to aller¬
gens in healthy and allergic individuals, providing methods for
verifying the responses in a reproducible and dose dependent
manner. Dissecting the immune responses to allergens at cellular
and molecular levels provides models for studying the different as¬
pects of T cell activation and the development of immunologic
memory and effector functions. A deep understanding of these
mechanisms will fundamentally change the current practice of al¬
lergy diagnosis, treatment, and prevention.
viii CONTENTS
Recognition of Lipids from Pollens by CDl Restricted T Cells 79
Fabrizio Spinozzi and Steven A. Porcelli
Allergic rhinitis and asthma should be considered as organ specific
inflammatory diseases in which the genetic background has deter¬
mined a local overproduction of Th2 type cytokines and an overex
pansion of particular APCs and T cells. Among the latter, a
potential pathogenetic role could be assumed for natural killer T
cells, expressing both invariant (Va24/Vpil) and classic ap or y5
T cell receptors. Recent studies support this notion and also sug¬
gest that surface pollen substances of nonprotein structure, such
as lipid components recognized by CD1, could be viewed as one
of the foreign materials against which the immune system of the
allergic subject can mount a local inflammatory response.
Chimeric Human Fey—Allergen Fusion Proteins
in the Prevention of Allergy 93
Ke Zhang, Daocheng Zhu, Christopher Kepley,
Tetsuya Terada, and Andrew Saxon
Allergic responses are strongly associated with Th2 type immune
responses, and modulation of the skewed Th2 response toward a
more balanced response is the major goal of allergen immunother
apy (IT) in allergic disorders. To achieve this goal, several ap¬
proaches have been tested. The authors previously showed that a
human immunoglobulin (Ig) Fey—Fce fusion protein (GE2) that di¬
rectly cross links FceRI and FcyRIIb on human mast cells and baso
phils was able to inhibit degranulation, and they reasoned that
human gamma—allergen fusion protein would achieve a similar
inhibitory effect in an allergen specific fashion while preserving
the immunogenicity of the allergen component. Therefore, the
authors constructed and developed a human—cat chimeric fusion
protein composed of the human Fcyl and the cat allergen Fel dl
(Felis domesticus) for cat allergen—specific IT. This article sum¬
marizes the therapeutic features and potential of this novel fusion
protein for allergic IT.
New Perspectives for Use of Native and Engineered
Recombinant Food Proteins in Treatment of Food Allergy 105
Anna Nowak Wegrzyn
Food allergy has emerged as an important target for research on
curative treatment and prevention, with most efforts focusing on
peanut, cow s milk, and egg allergy. This article reviews the recent
developments in the potential treatments for IgE mediated food al¬
lergy using native and engineered recombinant food proteins.
CONTENTS *
A Rice Based Edible Vaccine Expressing Multiple
T Cell Epitopes to Induce Oral Tolerance and Inhibit Allergy 129
Fumio Takaiwa
Plant pollens are the most common cause of seasonal allergic dis¬
ease. The number of patients undergoing treatment for allergies
to the pollen of Japanese cedar (major antigens, Cry j 1 and Cry j
2) has increased steadily each year. A rice seed—based edible vac¬
cine has been shown to be effective for treating Japanese cedar pol
linosis. Rice seeds containing the major T cell epitopes derived
from cedar pollen allergens were orally administrated to mice be¬
fore systemic challenge with total pollen protein. Mucosal immune
tolerance leading to a reduction of allergen specific IgE, T cell
proliferative reactions, and histamine were induced, resulting in
suppression of allergy specific symptoms such as sneezing. Oral
seed based peptide immunotherapy offers a safe, simple, and
cost effective alternative to conventional allergen specific immu¬
notherapy using crude allergen extracts for treating allergic dis¬
ease. A human version of rice seed—based edible vaccine
containing seven T cell epitopes from the Cry j 1 and Cry j 2 aller¬
gens was recently developed and is undergoing safety assessments.
Index 141
x rriMTPNW
|
| adam_txt |
NOVEL ASPECTS OF NATIVE AND RECOMBINANT ALLERGENS
AND THEIR THERAPEUTIC IMPLICATIONS
CONTENTS
Foreword xiii
Rafeul Alam
Preface xv
Sanjiv Sur
Bioinformatics Approaches to Classifying Allergens
and Predicting Cross Reactivity 1
Catherine H. Schein, Ovidiu Ivanciuc, and Werner Braun
Allergenic proteins from very different environmental sources have
similar sequences and structures. This fact may account for multi¬
ple allergen syndromes, whereby a myriad of diverse plants and
foods may induce a similar IgE based reaction in certain patients.
Identifying the common triggering protein in these sources, in sil
ico, can aid designing individualized therapy for allergen sufferers.
This article provides an overview of databases on allergenic pro¬
teins, and ways to identify common proteins that may be the cause
of multiple allergy syndromes. The major emphasis is on the rela¬
tional Structural Database of Allergenic Proteins (SDAP |http:/7
fermi.utmb.edu/SDAP/]), which includes cross referenced data
on the sequence, structure, and IgE epitopes of over 800 allergenic
proteins, coupled with specially developed bioinformatics tools to
group all allergens and identify discrete areas that may account for
cross reactivity. SDAP is freely available on the Web to clinicians
and patients.
Calcium Binding Proteins and their Role in Allergic Diseases 29
Nicole Wopfner, Oliver Dissertori, Fatima Ferreira,
and Peter Lackner
Calcium binding proteins (CBPs) are ubiquitous pollen aller¬
gens and important food allergens in fish and amphibians.
VOLUME 27 • NUMBER 1 • FEBRUARY 2007 vii
Calcium binding allergens containing two EF hands (polcalcins)
have been detected and characterized in pollen from trees, grasses,
and weeds. Timothy grass Phi p 7 is the most cross reactive
allergen among polcalcins. Although there is cross reactivity de¬
scribed within the subfamilies of calcium binding allergens, there
are no strong indications for IgE cross reactivity between CBPs
from plants, fish, and humans. Therefore, Phi p 7 could be used
as marker to identify multiple pollen sensitized patients, whereas
cod Gad c 1 or carp Cyp c 1 could be selected for the diagnosis
of fish allergy. Horn s 4, a calcium binding autoantigen, might be
an interesting candidate to monitor chronic skin inflammation in
atopic and nonatopic individuals. Diagnostic tests containing these
molecules could allow the identification of most patients sensitized
to calcium binding allergens/antigens. In general, IgE recognition
of calcium binding allergens is influenced by binding or release
of calcium ions. This knowledge could be used to engineer hypoal
lergenic CBPs for specific immunotherapy.
Pollen NAD(P)H Oxidases and their Contribution
to Allergic Inflammation 45
Nilesh G. Dharajiya, Attila Bacsi, Istvan Boldogh,
and Sanjiv Sur
This article provides an overview of NADPH oxidase and its role in
allergic inflammation. A background and historical perspectives of
NADPH oxidase are first provided, followed by a detailed over¬
view of mammalian NADPH oxidase subunits and their functional
organization. Plant NADPH oxidase, the authors' discovery of
NADPH oxidase in pollens, and their contribution to allergic in¬
flammation are then discussed, concluding with a discussion of fu¬
ture directions and outstanding questions that require attention.
Impact of Native, Recombinant, and Cross Reactive Allergens
on Humoral and T Cell—Mediated Immune Responses 65
Reto Crameri and Claudio Rhyner
Many native allergens have been purified to homogeneity from
natural sources, and whole arrays of recombinant and cross reac¬
tive allergens have been produced in large amounts as biologically
active molecules. These allergens offer potent research tools to in¬
vestigate humoral and Tcell—mediated immune responses to aller¬
gens in healthy and allergic individuals, providing methods for
verifying the responses in a reproducible and dose dependent
manner. Dissecting the immune responses to allergens at cellular
and molecular levels provides models for studying the different as¬
pects of T cell activation and the development of immunologic
memory and effector functions. A deep understanding of these
mechanisms will fundamentally change the current practice of al¬
lergy diagnosis, treatment, and prevention.
viii CONTENTS
Recognition of Lipids from Pollens by CDl Restricted T Cells 79
Fabrizio Spinozzi and Steven A. Porcelli
Allergic rhinitis and asthma should be considered as organ specific
inflammatory diseases in which the genetic background has deter¬
mined a local overproduction of Th2 type cytokines and an overex
pansion of particular APCs and T cells. Among the latter, a
potential pathogenetic role could be assumed for natural killer T
cells, expressing both invariant (Va24/Vpil) and classic ap or y5
T cell receptors. Recent studies support this notion and also sug¬
gest that surface pollen substances of nonprotein structure, such
as lipid components recognized by CD1, could be viewed as one
of the foreign materials against which the immune system of the
allergic subject can mount a local inflammatory response.
Chimeric Human Fey—Allergen Fusion Proteins
in the Prevention of Allergy 93
Ke Zhang, Daocheng Zhu, Christopher Kepley,
Tetsuya Terada, and Andrew Saxon
Allergic responses are strongly associated with Th2 type immune
responses, and modulation of the skewed Th2 response toward a
more balanced response is the major goal of allergen immunother
apy (IT) in allergic disorders. To achieve this goal, several ap¬
proaches have been tested. The authors previously showed that a
human immunoglobulin (Ig) Fey—Fce fusion protein (GE2) that di¬
rectly cross links FceRI and FcyRIIb on human mast cells and baso
phils was able to inhibit degranulation, and they reasoned that
human gamma—allergen fusion protein would achieve a similar
inhibitory effect in an allergen specific fashion while preserving
the immunogenicity of the allergen component. Therefore, the
authors constructed and developed a human—cat chimeric fusion
protein composed of the human Fcyl and the cat allergen Fel dl
(Felis domesticus) for cat allergen—specific IT. This article sum¬
marizes the therapeutic features and potential of this novel fusion
protein for allergic IT.
New Perspectives for Use of Native and Engineered
Recombinant Food Proteins in Treatment of Food Allergy 105
Anna Nowak Wegrzyn
Food allergy has emerged as an important target for research on
curative treatment and prevention, with most efforts focusing on
peanut, cow's milk, and egg allergy. This article reviews the recent
developments in the potential treatments for IgE mediated food al¬
lergy using native and engineered recombinant food proteins.
CONTENTS *
A Rice Based Edible Vaccine Expressing Multiple
T Cell Epitopes to Induce Oral Tolerance and Inhibit Allergy 129
Fumio Takaiwa
Plant pollens are the most common cause of seasonal allergic dis¬
ease. The number of patients undergoing treatment for allergies
to the pollen of Japanese cedar (major antigens, Cry j 1 and Cry j
2) has increased steadily each year. A rice seed—based edible vac¬
cine has been shown to be effective for treating Japanese cedar pol
linosis. Rice seeds containing the major T cell epitopes derived
from cedar pollen allergens were orally administrated to mice be¬
fore systemic challenge with total pollen protein. Mucosal immune
tolerance leading to a reduction of allergen specific IgE, T cell
proliferative reactions, and histamine were induced, resulting in
suppression of allergy specific symptoms such as sneezing. Oral
seed based peptide immunotherapy offers a safe, simple, and
cost effective alternative to conventional allergen specific immu¬
notherapy using crude allergen extracts for treating allergic dis¬
ease. A human version of rice seed—based edible vaccine
containing seven T cell epitopes from the Cry j 1 and Cry j 2 aller¬
gens was recently developed and is undergoing safety assessments.
Index 141
x rriMTPNW |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV022361898 |
| callnumber-first | R - Medicine |
| callnumber-label | RC583 |
| callnumber-raw | RC583 |
| callnumber-search | RC583 |
| callnumber-sort | RC 3583 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XD 2800 |
| ctrlnum | (OCoLC)93806013 (DE-599)BVBBV022361898 |
| dewey-full | 616.0798 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.0798 |
| dewey-search | 616.0798 |
| dewey-sort | 3616.0798 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01815nam a2200469 cb4500</leader><controlfield tag="001">BV022361898</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20070411 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">070322s2007 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">141604325X</subfield><subfield code="9">1-4160-4325-X</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781416043256</subfield><subfield code="9">978-1-4160-4325-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)93806013</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV022361898</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-29</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC583</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.0798</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XD 2800</subfield><subfield code="0">(DE-625)152549:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Novel aspects of native and recombinant allergens and their therapeutic implications</subfield><subfield code="c">guest ed.: Sanjiv Sur</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia, Pa. [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVIII, 144 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Immunology and allergy clinics of North America</subfield><subfield code="v">27,1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergens</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergens</subfield><subfield code="x">immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergens</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antigens</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypersensitivity</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Recombinant Proteins</subfield><subfield code="x">immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Recombinant Proteins</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Allergen</subfield><subfield code="0">(DE-588)4001255-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Allergen</subfield><subfield code="0">(DE-588)4001255-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sur, Sanjiv</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Immunology and allergy clinics of North America</subfield><subfield code="v">27,1</subfield><subfield code="w">(DE-604)BV000645505</subfield><subfield code="9">27,1</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015571225&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015571225</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV022361898 |
| illustrated | Illustrated |
| index_date | 2024-07-02T17:03:35Z |
| indexdate | 2024-07-09T20:55:58Z |
| institution | BVB |
| isbn | 141604325X 9781416043256 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015571225 |
| oclc_num | 93806013 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-29 |
| owner_facet | DE-355 DE-BY-UBR DE-29 |
| physical | XVIII, 144 S. Ill., graph. Darst. |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Saunders |
| record_format | marc |
| series | Immunology and allergy clinics of North America |
| series2 | Immunology and allergy clinics of North America |
| spelling | Novel aspects of native and recombinant allergens and their therapeutic implications guest ed.: Sanjiv Sur Philadelphia, Pa. [u.a.] Saunders 2007 XVIII, 144 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Immunology and allergy clinics of North America 27,1 Allergens Allergens immunology Allergens therapeutic use Antigens Hypersensitivity therapy Recombinant Proteins immunology Recombinant Proteins therapeutic use Allergen (DE-588)4001255-4 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Allergen (DE-588)4001255-4 s DE-604 Sur, Sanjiv Sonstige oth Immunology and allergy clinics of North America 27,1 (DE-604)BV000645505 27,1 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015571225&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Novel aspects of native and recombinant allergens and their therapeutic implications Immunology and allergy clinics of North America Allergens Allergens immunology Allergens therapeutic use Antigens Hypersensitivity therapy Recombinant Proteins immunology Recombinant Proteins therapeutic use Allergen (DE-588)4001255-4 gnd |
| subject_GND | (DE-588)4001255-4 (DE-588)4143413-4 |
| title | Novel aspects of native and recombinant allergens and their therapeutic implications |
| title_auth | Novel aspects of native and recombinant allergens and their therapeutic implications |
| title_exact_search | Novel aspects of native and recombinant allergens and their therapeutic implications |
| title_exact_search_txtP | Novel aspects of native and recombinant allergens and their therapeutic implications |
| title_full | Novel aspects of native and recombinant allergens and their therapeutic implications guest ed.: Sanjiv Sur |
| title_fullStr | Novel aspects of native and recombinant allergens and their therapeutic implications guest ed.: Sanjiv Sur |
| title_full_unstemmed | Novel aspects of native and recombinant allergens and their therapeutic implications guest ed.: Sanjiv Sur |
| title_short | Novel aspects of native and recombinant allergens and their therapeutic implications |
| title_sort | novel aspects of native and recombinant allergens and their therapeutic implications |
| topic | Allergens Allergens immunology Allergens therapeutic use Antigens Hypersensitivity therapy Recombinant Proteins immunology Recombinant Proteins therapeutic use Allergen (DE-588)4001255-4 gnd |
| topic_facet | Allergens Allergens immunology Allergens therapeutic use Antigens Hypersensitivity therapy Recombinant Proteins immunology Recombinant Proteins therapeutic use Allergen Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015571225&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000645505 |
| work_keys_str_mv | AT sursanjiv novelaspectsofnativeandrecombinantallergensandtheirtherapeuticimplications |